<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Effectiveness of Ivabradine Treatment in Different Subpopulations with Stable Angina in Clinical Practice: A Pooled Analysis of Observational Studies</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
				<date type="published" when="2016-06-23">June 23, 2016</date>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author role="corresp">
							<persName><forename type="first">Karl</forename><surname>Werdan</surname></persName>
							<email>karl.werdan@medizin.uni-halle.de</email>
							<affiliation key="aff0">
								<orgName type="department">Department of Medicine and Heart Centre</orgName>
								<orgName type="institution">University Hospital of the Martin Luther University of Halle-Wittenberg, Halle (Saale)</orgName>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Stefan</forename><surname>Perings</surname></persName>
							<affiliation key="aff1">
								<orgName type="institution">CardioCentrum</orgName>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Ralf</forename><surname>Köster</surname></persName>
							<affiliation key="aff3">
								<orgName type="department">Department of Cardiology and Angiology</orgName>
								<orgName type="institution">Johanniter Hospital</orgName>
								<address>
									<settlement>Geesthacht</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Malte</forename><surname>Kelm</surname></persName>
							<affiliation key="aff2">
								<orgName type="department">Department of Cardiology, Pneumology and Angiology</orgName>
								<orgName type="institution">Düsseldorf University Hospital</orgName>
								<address>
									<settlement>Düsseldorf</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Thomas</forename><surname>Meinertz</surname></persName>
							<affiliation key="aff4">
								<orgName type="department">Department of Cardiology and Angiology</orgName>
								<orgName type="institution">University Heart Center</orgName>
								<address>
									<settlement>Hamburg</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Georg</forename><surname>Stöckl</surname></persName>
							<affiliation key="aff5">
								<orgName type="department">Department of Medical Affairs</orgName>
								<orgName type="institution">Servier Deutschland GmbH</orgName>
								<address>
									<settlement>Munich</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Ursula</forename><surname>Müller-Werdan</surname></persName>
							<affiliation key="aff6">
								<orgName type="department">Department of Geriatrics</orgName>
								<orgName type="institution" key="instit1">Evangelisches Geriatriezentrum, and h Chair of Geriatrics</orgName>
								<orgName type="institution" key="instit2">Charité -Universitätsmedizin Berlin</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>Prof</roleName><forename type="middle">Karl</forename><surname>Werdan</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Werdan</forename><forename type="middle">/</forename><surname>Perings</surname></persName>
						</author>
						<author>
							<persName><forename type="first">/</forename><surname>Köster</surname></persName>
						</author>
						<author>
							<persName><forename type="first">/</forename><surname>Kelm</surname></persName>
						</author>
						<author>
							<persName><forename type="first">/</forename><surname>Meinertz</surname></persName>
						</author>
						<author>
							<persName><forename type="first">/</forename><surname>Stöckl</surname></persName>
						</author>
						<author>
							<persName><forename type="first">/</forename><surname>Müller-Werdan</surname></persName>
						</author>
						<author>
							<affiliation key="aff7">
								<orgName type="department">Department of Medicine and Heart Centre</orgName>
								<orgName type="institution">Martin Luther University of Halle-Wittenberg</orgName>
								<address>
									<addrLine>Ernst-Grube-Strasse 40</addrLine>
									<postCode>DE-06120</postCode>
									<settlement>Halle (Saale)</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Effectiveness of Ivabradine Treatment in Different Subpopulations with Stable Angina in Clinical Practice: A Pooled Analysis of Observational Studies</title>
					</analytic>
					<monogr>
						<imprint>
							<date type="published" when="2016-06-23">June 23, 2016</date>
						</imprint>
					</monogr>
					<idno type="MD5">90CC77E76EF9C47B8E23F8D518C288A7</idno>
					<idno type="DOI">10.1159/000447443</idno>
					<note type="submission">Received: February 12, 2016 Accepted after revision: June 6, 2016</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:37+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>were available on 8,555 patients, where therapy with ivabradine was associated with a significant reduction in the frequency of angina attacks and consumption of short-acting nitrates of 87%.</s><s>Effectiveness was maintained in all investigated subpopulations, with a reduction in antianginal parameters of 82-90%.</s><s>Clinical status (Canadian Cardiovascular Society class) and quality of life were also improved.</s><s>Ivabradine was well tolerated in all subgroups.</s><s>Conclusions: Ivabradine is effective and safe in all subpopulations of angina patients seen in clinical practice, independent of age, comorbidities, and use of beta-blocker.</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Introduction</head><p><s>Uncontrolled heart rate can induce or worsen myocardial ischemia and angina symptoms by disrupting myocardial oxygen balance <ref type="bibr" target="#b0">[1,</ref><ref type="bibr" target="#b1">2]</ref> .</s><s>Elevated heart rate increases the demand of myocardial oxygen and at the same time limits oxygen supply to the heart by reducing the time for diastolic perfusion.</s><s>Both mechanisms contribute to myocardial ischemia, making heart rate reduction an obvious strategy to prevent oxygen imbalance and improve angina symptoms <ref type="bibr" target="#b2">[3]</ref> .</s><s>Such a strategy can be achieved by using a beta-blocker, which is a well-established treatment to control the heart rate and symptoms in stable angina patients <ref type="bibr" target="#b3">[4]</ref> .</s><s>However, besides their effects on heart rate, beta-blockers have additional properties that can negatively affect cardiac function <ref type="bibr" target="#b2">[3]</ref> .</s><s>Ivabradine, an inhibitor of the I f pacemaker current, selectively targets the heart rate and, in contrast to beta-blockers, does not reduce myocardial contractility or relaxation <ref type="bibr" target="#b4">[5]</ref> .</s><s>The mechanisms of anti-ischemic and antianginal efficacy of ivabradine were first elucidated in experimental studies <ref type="bibr" target="#b4">[5]</ref> and confirmed in recent clinical trials.</s><s>This includes an increase in myocardial diastolic perfusion time <ref type="bibr" target="#b5">[6]</ref> , enhancement in coronary flow reserve <ref type="bibr" target="#b6">[7]</ref> , improvement in endothelial function <ref type="bibr" target="#b7">[8]</ref> , and enhancement in coronary collateral flow in patients with chronic stable coronary artery disease <ref type="bibr" target="#b8">[9]</ref> .</s><s>This makes ivabradine an important antianginal and anti-ischemic therapeutic strategy.</s></p><p><s>The anti-ischemic effect of ivabradine had been demonstrated in a range of randomized clinical trials (RCTs) <ref type="bibr" target="#b9">[10]</ref><ref type="bibr" target="#b10">[11]</ref><ref type="bibr" target="#b11">[12]</ref><ref type="bibr" target="#b12">[13]</ref><ref type="bibr" target="#b13">[14]</ref> , supporting its use for the treatment of symptoms in patients with stable angina alone or in combination with a beta-blocker <ref type="bibr">[15]</ref> .</s><s>Moreover, the antianginal efficacy of ivabradine has been established across a variety of subpopulations with diverse comorbidities, as demonstrated by a pooled analysis of five RCTs <ref type="bibr" target="#b16">[16]</ref> .</s><s>However, patients seen in clinical practice often differ from those included in RCTs and may not respond similarly to treatment.</s><s>The stringent inclusion/exclusion criteria used in RCTs, with the frequent exclusion of elderly patients and patients with comorbidities, usually lead to populations with a lower risk profile compared with real-world settings <ref type="bibr" target="#b17">[17]</ref> .</s><s>Therefore, the question of the effect of ivabradine in patients with stable angina seen in everyday routine practice has been addressed in a range of observational studies, which confirmed both the effectiveness and safety of the drug when assessed in real-life situations <ref type="bibr" target="#b18">[18]</ref><ref type="bibr" target="#b19">[19]</ref><ref type="bibr" target="#b20">[20]</ref> .</s><s>The question remains whether this beneficial effect observed in real clinical practice in a broad population still applies to subpopulations with specific characteristics.</s></p><p><s>The aim of the study described here was to assess the effectiveness and safety of ivabradine in different subpopulations of stable angina patients in clinical practice.</s><s>This was achieved by pooling the data from three available observational trials: ADDITIONS (Practical Daily Efficacy and Safety of Procoralan ® in Combination with Beta-Blockers) <ref type="bibr" target="#b18">[18]</ref> , REDUCTION (Reduction of Ischemic Events by Reduction of Heart Rate in the Treatment of Stable Angina with Ivabradine) <ref type="bibr" target="#b19">[19]</ref> , and RESPONSIfVE (Evaluation of Effectiveness and Therapeutic Response to Ivabradine in Daily Practical Use for Chronic Stable Angina Patients) <ref type="bibr" target="#b20">[20]</ref> , which led to a population large enough for meaningful subgroup analysis.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Patients and Methods</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Participants and Study Design</head><p><s>Data were pooled from three German observational studies: ADDITIONS <ref type="bibr" target="#b18">[18]</ref> , REDUCTION <ref type="bibr" target="#b19">[19]</ref> , and RESPONSIfVE <ref type="bibr" target="#b20">[20]</ref> ( table <ref type="table" target="#tab_0">1</ref> ).</s><s>These were multicenter, open-label, prospective studies including patients with stable angina pectoris in 818, 1,503, and 338 centers in Germany, respectively.</s><s>The studies were chosen for analysis as they are the only published and large-scale (each &gt;1,000 patients) German observational cohorts for ivabradine use in its angina indication.</s><s>These cohorts show very similar inclusion and evaluation criteria with detailed documentation and follow-up of patients.</s><s>This provides a representative picture of treatment practice with ivabradine in Germany from three studies with relatively low heterogeneity.</s><s>All investigators (general practitioners, internal medicine physicians, or cardiologists in private practice) filled out a standardized clinical questionnaire during the patient's treatment that included the following information: medical history and concomitant medication, heart rate, Canadian Cardiovascular Society (CCS) classification, number of angina attacks, consumption of short-acting nitrates, and quality of life using the EQ-5D index and EQ VAS (visual analog scale) scores.</s><s>Patients were only eligible for inclusion if they had given their written informed consent.</s><s>For 47 patients in the REDUC-TION study, questionnaires were filled out at the end of the study rather than on an ongoing basis, and those patients were excluded from the original trial report <ref type="bibr" target="#b19">[19]</ref> .</s><s>However, these data can still be considered as valid, and these 47 patients (including 24 patients with available effectiveness data) were included in the present pooled effectiveness and safety analysis.</s><s>All patients in the RESPONSIfVE trial were included in the pooled analysis, whereas three patients in the ADDITIONS trial with unclear betablocker therapy were excluded.</s><s>All three studies were conducted in accordance with the Declaration of Helsinki and complied with the ethical guidelines of the European Independent Ethics Committee.</s></p><p><s>The three studies had similar inclusion criteria: patients with a resting heart rate ≥ 60 bpm and in need of symptomatic treatment for stable angina pectoris.</s><s>The main difference related to the use of beta-blocker therapy: concomitant treatment with beta-blocker was part of the inclusion criteria for the ADDITIONS trial <ref type="bibr" target="#b18">[18]</ref> , while it was optional for both the REDUCTION and RESPON-SIfVE trials <ref type="bibr" target="#b19">[19,</ref><ref type="bibr" target="#b20">20]</ref> ( table <ref type="table" target="#tab_0">1</ref> ).</s></p><p><s>The study design was similar in all studies, with three scheduled visits: the first visit performed at baseline and the following two visits after approximately 1 and 4 months of treatment.</s><s>After the baseline visit, therapy was started with ivabradine 5 mg b.i.d. and could be increased to 7.5 mg b.i.d. after 2-4 weeks.</s><s>A lower dose of 2.5 mg b.i.d.</s><s>could be considered in patients with severe renal dysfunction (creatinine clearance &lt;15 ml/min) or a low resting heart rate (&lt;50 bpm) during treatment, or in the elderly ( ≥ 75 years).</s><s>Follow-up lasted 4 months.</s><s>Further details of the study designs can be found in the respective publications of the trials <ref type="bibr" target="#b18">[18]</ref><ref type="bibr" target="#b19">[19]</ref><ref type="bibr" target="#b20">[20]</ref> .</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Definition of Subpopulations</head><p><s>The pooled data were analyzed in different subpopulations of interest defined according to the following baseline criteria: gender, age ( ≥ 75 years), heart rate ( ≥ 70 bpm), angina severity (CCS classification), concomitant medication (any beta-blockers or metoprolol), previous percutaneous coronary intervention (PCI), or comorbidities: previous myocardial infarction (MI), diabetes, asthma/chronic obstructive pulmonary disease (COPD), and renal dysfunction.</s><s>The effectiveness of ivabradine was also assessed in patients with concomitant metoprolol and heart rate ≥ 70 bpm, closely reflecting the practical application of ivabradine in combination with the most commonly used beta-blocker in the analyzed studies.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Measured Parameters and Statistical Methods</head><p><s>The following parameters were evaluated for effectiveness in the pooled data set: resting heart rate (determined after at least 5 min at rest by manual assessment or ECG recording), number of angina attacks, use of short-acting nitrates, and CCS classification.</s><s>Quality of life data (EQ-5D index and EQ VAS scores) were only available for the ADDITIONS trial.</s><s>Absolute and relative changes from baseline were analyzed by a one-sample t test.</s><s>Changes in CCS classification were analyzed by the signed-rank test.</s><s>Safety was assessed by analyzing the frequency of adverse events, which were coded with MedDRA version 17.1.</s><s>All analyses were performed in a descriptive manner using SAS software (version 9.3), without any formal testing of predefined statistical hypotheses.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Results</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Characteristics of the Pooled Population</head><p><s>The pooled population used for effectiveness analysis comprised a total of 8,555 patients with available data: 2,327 patients from the ADDITIONS trial, 4,978 patients from the REDUCTION trial, and 1,250 patients from the RESPONSIfVE trial.</s></p><p><s>The baseline characteristics of the pooled population are presented in table 2 : mean age was 65.4 years, 41% were female, and 19% were ≥ 75 years.</s><s>Half of the population had undergone PCI (49%), and about two fifths (41%) had a history of MI.</s><s>Hypertension and dyslipidemia were present in the vast majority of patients (91 and 80%, respectively).</s><s>Diabetes (46%) and asthma/COPD (35%) were frequent, while renal dysfunction was less common (6%).</s><s>Patients had a mean heart rate of 83.3 bpm at baseline and experienced a mean of 2.1 angina attacks per week.</s><s>The distribution of CCS classification was 27% for class I, 53% for class II, and 20% for class III + IV.</s></p><p><s>Concerning angina related-treatments, 40% of patients were receiving a beta-blocker at baseline (predominantly metoprolol: 16%), 19% a calcium antagonist, and 18% a long-acting nitrate.</s><s>Other concomitant medications were typical of those used in cardiovascular patients: aspirin (77%), statins (64%), and angiotensinconverting enzyme inhibitors (49%).</s></p><p><s>Concerning quality of life parameters, aged patients ( ≥ 75 years) had a lower quality of life at baseline com- pared with younger patients (EQ-5D: 0.57 ± 0.28 for ≥ 75 years vs. 0.68 ± 0.26 for &lt;75 years; EQ VAS score: 52.8 ± 17.50 28 for ≥ 75 years vs. 58.5 ± 18.34 for &lt;75 years).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Effect of Ivabradine on Heart Rate</head><p><s>Heart rate was reduced from 83.3 ± 14.13 bpm at baseline to 72.7 ± 10.48 bpm after 1 month (12% relative reduction) and to 68.6 ± 9.07 bpm after 4 months of ivabradine treatment (16% relative reduction).</s><s>Overall, 85% of patients had achieved a heart rate &lt;70 bpm or a reduc-tion in heart rate of ≥ 10 bpm after 4 months of treatment (58% with heart rate &lt;70 bpm and 69% with heart rate reduction of ≥ 10 bpm).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Antianginal Effectiveness of Ivabradine</head><p><s>In the overall population, treatment with ivabradine was associated with a progressive reduction in the mean number of angina attacks per week (from 2.1 ± 2.79 at baseline to 0.7 ± 1.86 and 0.3 ± 1.25 at 1 and 4 months, respectively; fig. <ref type="figure" target="#fig_0">1 a</ref>).</s><s>A similar decrease was observed for use of short-acting nitrates per week (from 2.8 ± 3.95 at baseline to 1.0 ± 2.12 and 0.4 ± 1.40 at 1 and 4 months, respectively; fig. <ref type="figure" target="#fig_0">1 b</ref>).</s><s>Treatment with ivabradine was also associated with a significant improvement in the clinical status of the overall population assessed by the distribution of CCS class ( fig. <ref type="figure" target="#fig_0">1 c</ref>).</s><s>The majority of patients shifted to class I at the end of the study treatment (from 27% at baseline to 67% at 4 months), while the proportion of patients in the more severe classes was substantially reduced (class II: from 53% at baseline to 29% at 4 months; class III + IV: from 20% at baseline to 4% at 4 months).</s></p><p><s>A similar pattern in antianginal effectiveness was observed in patients receiving concomitant metoprolol at baseline ( fig. <ref type="figure" target="#fig_1">2</ref> ).</s><s>In that subset of patients, the mean number of angina attacks progressively decreased from 1.6 ± 2.20 at baseline to 0.5 ± 1.20 and 0.3 ± 0.91 at 1 and 4 months, respectively.</s><s>Use of short-acting nitrates was reduced from 2.2 ± 3.26 at baseline to 0.7 ± 1.43 and 0.3 ± 1.08 at 1 and 4 months, respectively.</s><s>Finally, an improvement in CCS class distribution was noted at the end of the study, with the majority of patients (64%) graded as class I at the last visit (baseline: 26%) and fewer patients as class II (32%) and III + IV (4%; versus 51 and 22%, respectively, at baseline).</s><s>The effects of ivabradine on angina attacks, nitrate use, and CCS reclassification were comparable for other concomitantly used cardioselective betablockers (bisoprolol, carvedilol, and nebivolol).</s></p><p><s>The antianginal effectiveness of ivabradine in various subpopulations of interest defined by demographic characteristics, heart rate at baseline, angina severity, comorbidities, and concomitant medication, is presented in figure 3 .</s><s>The relative reduction in the number of angina attacks per week at 4 months was consistent among all investigated subgroups, ranging from 82 to 90%, and was comparable to that seen in the overall population (87%).</s><s>Similar findings were observed for use of short-acting nitrates, with a consistent relative reduction in all subgroups (from 82 to 90%), in line with the overall reduction of 87% in the pooled population.</s><s>Values are means ± SD or n (%) of patients.</s><s>ACE = Angiotensin-converting enzyme.</s></p><p><s>a Quality of life was only available for the ADDITIONS trial.</s></p><p><s>Quality of life data at 4 months, assessed by the EQ-5D index and VAS scores, are presented in table 3 for the overall ADDITIONS population and subgroups of interest.</s><s>As previously shown, ivabradine significantly improved quality of life parameters in the whole population as well as in patients with previous PCI and with concomitant metoprolol medication <ref type="bibr" target="#b18">[18,</ref><ref type="bibr" target="#b21">21,</ref><ref type="bibr" target="#b22">22]</ref> .</s><s>Here, we extend the findings to a larger range of patient subgroups, where ivabradine showed consistent improvement in quality of life, using both measurement systems, in all  considered subgroups (absolute changes from baseline ranging from 0.11 ± 0.18 to 0.26 ± 0.28 for EQ-5D index and from 6.3 ± 9.60 to 16.2 ± 16.94 for EQ VAS score; p &lt; 0.0001 for all changes).</s><s>Beta-blocker treatment was stopped in 1% (n = 79) and initiated in 0.4% (n = 36) of patients in the total cohort during the study period.</s><s>Ivabradine was discontinued in 4% (n = 361) of patients.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Safety and Tolerability</head><p><s>The pooled population considered for analysis of safety included a total of 8,578 patients: 2,327 patients for the ADDITIONS trial, 5,001 patients for the REDUCTION trial, and 1,250 patients for the RESPONSIfVE trial.</s></p><p><s>Overall, adverse drug reactions were rare (1.2% of patients, n = 99) and mainly not serious.</s><s>Nausea (0.2%, n = 15), dizziness (0.2%, n = 14), photopsia (0.2%, n = 13), and bradycardia (0.1%, n = 9) were the most reported reactions.</s><s>The frequency and type of adverse drug reactions were similar in the overall population and in all analyzed subgroups, including in older ( ≥ 75 years) versus younger (&lt;75 years) patients (1.5 vs. 1.1%, respectively).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Discussion</head><p><s>This pooled analysis shows that the antianginal effectiveness of ivabradine is similar across a large range of subpopulations of stable angina patients seen in realworld clinical practice.</s><s>Our results indicate that ivabradine is associated with a sustained and significant reduction in angina attacks and consumption of short-act- ing nitrates, and an improvement in CCS class (reflecting exercise tolerance) and quality of life.</s><s>These results were consistent in all analyzed subgroups, including women, the elderly, patients with a history of PCI or MI, and patients on beta-blockers.</s><s>In addition, the drug had a good safety and tolerability profile in all considered subgroups.</s></p><p><s>Compared with pooled randomized trials with ivabradine <ref type="bibr" target="#b16">[16]</ref> , the patients in our study were older ( ≥ 75 years: 19 vs. 4%) and more often women (41 vs. 18%).</s><s>They also presented with a higher heart rate at baseline (83.3 vs. 73.0</s><s>bpm) and more hypertension (91 vs. 59%), dyslipidemia (80 vs. 53%), diabetes (46 vs. 19%), and asthma/COPD (35 vs. 6%).</s><s>Thus, this pooled analysis complements and extends the demonstration of efficacy and safety of ivabradine in a broader population from that seen in randomized trials <ref type="bibr" target="#b9">[10]</ref><ref type="bibr" target="#b10">[11]</ref><ref type="bibr" target="#b11">[12]</ref><ref type="bibr" target="#b12">[13]</ref><ref type="bibr" target="#b13">[14]</ref> .</s></p><p><s>Among the subpopulations analyzed, the elderly deserve attention as they represent a growing population of stable angina patients with specific characteristics.</s><s>Elderly patients are often underrepresented in RCTs <ref type="bibr" target="#b23">[23]</ref> , and diagnosis of coronary artery disease can be difficult as they can present with atypical symptoms <ref type="bibr" target="#b3">[4]</ref> .</s><s>Aged patients remain challenging to treat because of a higher prevalence of comorbidities and more frequent side effects or intolerance to drugs <ref type="bibr" target="#b24">[24]</ref> .</s><s>Reduction in angina attacks and consumption of short-acting nitrates has been previously shown in a subgroup of 91 elderly patients with stable angina in a pooled analysis of RCTs <ref type="bibr" target="#b16">[16]</ref> .</s><s>Here, we demonstrated the antianginal effectiveness of ivabradine in a sizeable population of more than 1,600 patients ≥ 75 years seen in real clinical practice.</s><s>In addition to the reduction in angina attacks (by 84%) and use of short-acting nitrates (by 82%), ivabradine significantly improved the quality of life in this aged population with impaired health status scores at baseline.</s><s>Importantly, all these beneficial effects were accompanied by a good safety profile, as ivabradine displayed a similar rate of adverse events compared with younger patients.</s></p><p><s>Nearly half (46%) of our population had diabetes.</s><s>Regular physical activity is an important part of the management of diabetes, and this may be impaired by angina <ref type="bibr" target="#b25">[25]</ref> .</s><s>Recent trial data indicate that 82% of patients with coronary artery disease and type 2 diabetes may have angina-related symptoms despite the use of recommended therapies <ref type="bibr" target="#b26">[26]</ref> .</s><s>The need for therapies that effectively reduce symptoms is thus essential.</s><s>Here, we demonstrated 148 a significant decrease in the number of angina attacks (by 86%) and use of short-acting nitrates (by 85%) with ivabradine in angina patients with diabetes.</s><s>Our data are consistent with the improvement in exercise tolerance and the reduction in angina symptoms observed in RCTs with ivabradine in subgroups of patients with angina and diabetes <ref type="bibr" target="#b16">[16,</ref><ref type="bibr" target="#b27">27]</ref> .</s><s>Diabetic patients often develop cardiac autonomic neuropathy, leading to elevated sympathetic tone and resting tachycardia <ref type="bibr" target="#b28">[28]</ref> .</s><s>Accordingly, in a recent survey, the resting heart rate of stable coronary artery disease patients with diabetes was 5 bpm higher than those without diabetes <ref type="bibr" target="#b29">[29]</ref> .</s><s>As a result, a large proportion of angina patients who have diabetes may be eligible for ivabradine treatment.</s><s>Another important point to consider is the potential detrimental effects of antianginal therapies, such as beta-blockers and calcium channel blockers, on the glycemic control of diabetic patients <ref type="bibr" target="#b25">[25]</ref> .</s><s>Importantly, ivabradine does not alter glycosylated hemoglobin HbA 1c and fasting glucose, whereas atenolol and amlodipine increase levels of both parameters <ref type="bibr" target="#b27">[27]</ref> .</s></p><p><s>Our results suggest that ivabradine is a safe and efficient treatment for angina patients with diabetes.</s><s>One fifth of patients report symptoms of angina 1 year after an event of acute MI <ref type="bibr" target="#b30">[30]</ref> .</s><s>Moreover, two fifths of patients with stable angina remain symptomatic despite revascularization <ref type="bibr" target="#b31">[31]</ref> .</s><s>In this study, patients with previous MI and PCI accounted for 41% (n = 3,405) and 49% (n = 4,073) of the pooled population, respectively.</s><s>Ivabradine decreased angina symptoms to the same extent in both subpopulations (angina attacks reduced by 86% and use of short-acting nitrates by 87%), consistent with the results of RCTs <ref type="bibr" target="#b16">[16]</ref> .</s><s>Of note, a recent report indicates that ivabradine can limit episodes of stunning in patients with coronary artery disease <ref type="bibr" target="#b32">[32]</ref> .</s><s>This cardioprotective effect, together with the anti-ischemic properties of ivabradine, could play a significant role in limiting the progression to myocardial hibernation and left ventricular dysfunction commonly observed in patients with a history of MI <ref type="bibr" target="#b33">[33]</ref> .</s><s>In addition, ivabradine was recently shown to improve endothelial function in coronary artery disease patients after PCI <ref type="bibr" target="#b7">[8]</ref> .</s><s>In many patients with ischemic heart disease, microvascular dysfunction is increasingly becoming recognized as an important mechanism of angina, in addition to the more classic obstructive atherosclerosis mechanism <ref type="bibr" target="#b34">[34]</ref> .</s><s>Microvascular dysfunction is particularly prominent in patients with recurrent angina after PCI <ref type="bibr" target="#b35">[35]</ref> .</s><s>By improving endothelial function, ivabradine may contribute to maintaining coronary dilation, hence preventing microvascular dysfunction and the recurrence of angina attacks after coronary intervention.</s></p><p><s>In addition to the pain and discomfort, angina symptoms impair the quality of life of patients by limiting their ordinary physical activities and altering their psychological well-being.</s><s>Patients with angina may further reduce their daily activities to prevent the occurrence of angina attacks, thereby contributing to the degradation of their quality of life.</s><s>Restoration of physical activity and functional capacity are thus a major goal of antianginal therapy.</s><s>Here, we show that ivabradine significantly improved the distribution of CCS class, with a majority of patients (67%) rated as class I at 4 months.</s><s>The proportion of patients with activity-limiting angina ( ≥ class II) decreased from 73 to 33%.</s><s>Accordingly, this reduction in angina severity was accompanied by an improvement in scores of quality of life, which include assessment of mobility, usual activities, and self-care.</s><s>This improvement was noted in all analyzed subpopulations, including patients with previous MI or PCI, diabetes, and the elderly.</s><s>These results indicate that ivabradine effectively improves health status and physical activities in a broad range of angina patients seen in clinical practice.</s></p><p><s>The incidence of adverse drug reactions, especially bradycardia, was considerably lower in our pooled analysis than in large, randomized outcome trials with ivabradine <ref type="bibr" target="#b36">[36]</ref><ref type="bibr" target="#b37">[37]</ref><ref type="bibr" target="#b38">[38]</ref> .</s><s>This might be explained by several factors.</s><s>The baseline (up to 11 bpm) and achieved heart rate (up to 9 bpm) was higher, and mean daily doses of ivabradine were lower (up to 5 mg/day) in our cohort, which may have contributed to prevent bradycardia and other dose-dependent adverse reactions in general.</s><s>Furthermore, the use of concomitant cardiovascular medication like beta blockers, ACE inhibitors, statins, and aspirin was considerably less pronounced in our study population, which might have also reduced susceptibility to adverse drug reactions, e.g. by avoidance of potential drug interactions.</s></p><p><s>In line with its indication, our results confirm the antianginal effectiveness of ivabradine in patients with an elevated heart rate ( ≥ 70 bpm), with a reduction in angina attacks and use of short-acting nitrates by 87%.</s><s>Moreover, the drug retained a similar effectiveness when used in combination with a beta-blocker.</s><s>When focusing on patients with an elevated heart rate despite the use of the most commonly prescribed beta-blocker, metoprolol <ref type="bibr" target="#b3">[4]</ref> , the number of angina attacks and use of short-acting nitrates were significantly reduced with the addition of ivabradine treatment (by 88 and 87%, respectively).</s><s>Despite the widespread use of beta-blockers, elevated heart rate persists in many patients and is associated with more frequent angina and ischemia <ref type="bibr" target="#b39">[39]</ref> .</s><s>Thus, the addition of ivabradine may be considered in all eligible patients with a heart rate ≥ 70 bpm, including those already treated by a beta-blocker, to further reduce the heart rate and improve symptoms of angina.</s></p><p><s>The main limitation of the present analysis is the lack of control group, which might have biased the results by overestimating the treatment effect.</s><s>Definitions of comorbidities were not prespecified and were left to the judgment of the physicians.</s><s>Another limitation may be the short treatment duration of 4 months, which on the other hand was sufficient to evaluate symptomatic effects of ivabradine in several controlled trials <ref type="bibr" target="#b9">[10,</ref><ref type="bibr" target="#b11">[12]</ref><ref type="bibr" target="#b12">[13]</ref><ref type="bibr" target="#b13">[14]</ref>] .</s><s>Antianginal efficacy and safety have also been shown for a longer period of 12 months in a randomized study <ref type="bibr" target="#b10">[11]</ref> .</s><s>Finally, observational trials can lead to an underestimation of adverse events, as they were spontaneously reported and not specifically sought.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Conclusion</head><p><s>We have shown, based on this short-term data, that ivabradine is an effective and well-tolerated antianginal treatment in a broad range of patients seen in real clinical practice, including diabetic patients as well as patients with previous MI and/or PCI.</s><s>Antianginal effectiveness was also maintained in the elderly and in patients with concomitant beta-blockers.</s><s>In addition, ivabradine improved the quality of life in all analyzed subpopulations.</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>Fig. 1 .</head><label>1</label><figDesc><div><p><s>Fig. 1.</s><s>Antianginal effectiveness of iva bradine in the overall population.</s><s>a Number of angina attacks/week.</s><s>b Use of short-acting nitrates/week.</s><s>c Distribution of CCS class.</s><s>Bars are means ± SD. * p &lt; 0.0001 for changes from baseline or CCS class changes.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>Fig. 2 .</head><label>2</label><figDesc><div><p><s>Fig. 2. Antianginal effectiveness of iva bradine in patients with concomitant metoprolol at baseline.</s><s>a Number of angina attacks/ week.</s><s>b Use of short-acting nitrates/week.</s><s>c Distribution of CCS class.</s><s>Bars are means ± SD. * p &lt; 0.0001 for changes from baseline or CCS class changes.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><head>Fig. 3 .</head><label>3</label><figDesc><div><p><s>Fig. 3. Antianginal effectiveness after 4 months of treatment with ivabradine in different subpopulations.</s><s>Bars are relative changes from baseline (means ± SD).</s><s>Values shown in bars are absolute changes from baseline (means ± SD). p &lt; 0.0001 for all changes.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>Table 1 .</head><label>1</label><figDesc><div><p><s><ref type="bibr" target="#b18">[18]</ref><ref type="bibr" target="#b19">[19]</ref><ref type="bibr" target="#b20">[20]</ref> and main effectiveness results of the ADDITIONS, REDUCTION, and RESPONSIfVE trials[18][19][20]</s></p></div></figDesc><table><row><cell></cell><cell>ADDITIONS</cell><cell>REDUCTION</cell><cell>RESPONSIfVE</cell></row><row><cell>Design</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Type of study</cell><cell>Observational, prospective,</cell><cell>Observational, prospective,</cell><cell>Observational, prospective,</cell></row><row><cell></cell><cell>in addition to beta-blocker</cell><cell>with contraindication or</cell><cell>with or without beta-blocker</cell></row><row><cell></cell><cell></cell><cell>intolerance to beta-blocker</cell><cell></cell></row><row><cell>Patients, n</cell><cell>2,330</cell><cell>4,954</cell><cell>1,250</cell></row><row><cell>Duration of ivabradine treatment</cell><cell>4 months</cell><cell>4 months</cell><cell>4 months</cell></row><row><cell>Mean dose after 4 months</cell><cell>12.37 mg/day</cell><cell>10.5 mg/day</cell><cell>11.1 mg/day</cell></row><row><cell>Main effectiveness results</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Resting heart rate, bpm</cell><cell>-19.4</cell><cell>-12.4</cell><cell>-15.4</cell></row><row><cell>Angina attacks/week, n</cell><cell>-1.4</cell><cell>-2.0</cell><cell>-1.1</cell></row><row><cell cols="2">Use of short-acting nitrates/week, n -1.9</cell><cell>-2.8</cell><cell>-1.4</cell></row><row><cell>CCS classification, % of patients</cell><cell></cell><cell>n.a.</cell><cell></cell></row><row><cell>Class I</cell><cell>Increased from 29 to 68%</cell><cell></cell><cell>Increased from 24 to 66%</cell></row><row><cell>Class II or III</cell><cell>Decreased from 70 to 32%</cell><cell></cell><cell>Decreased from 76 to 34%</cell></row><row><cell cols="4">Main effectiveness results are shown as mean change from baseline after 4 months of ivabradine treatment except for CCS classifica-</cell></row><row><cell>tion. n.a. = Not available.</cell><cell></cell><cell></cell><cell></cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head>Table 2 .</head><label>2</label><figDesc><div><p><s>Baseline characteristics in the pooled data set</s></p></div></figDesc><table><row><cell>Characteristic (number of patients with data)</cell><cell>Pooled</cell></row><row><cell></cell><cell>population</cell></row><row><cell>Demographic characteristics</cell><cell></cell></row><row><cell>Age (n = 8,525), years</cell><cell>65.4 ± 10.58</cell></row><row><cell>≥75 years (n = 8,525)</cell><cell>1,644 (19)</cell></row><row><cell>Female sex (n = 8,198)</cell><cell>3,347 (41)</cell></row><row><cell>Height (n = 8,329), cm</cell><cell>170.8 ± 8.37</cell></row><row><cell>Weight (n = 8,320), kg</cell><cell>81.4 ± 14.30</cell></row><row><cell>Medical history</cell><cell></cell></row><row><cell>Previous MI (n = 8,363)</cell><cell>3,405 (41)</cell></row><row><cell>Previous PCI (n = 8,387)</cell><cell>4,073 (49)</cell></row><row><cell>Hypertension (n = 7,763)</cell><cell>7,091 (91)</cell></row><row><cell>Dyslipidemia (n = 7,655)</cell><cell>6,124 (80)</cell></row><row><cell>Diabetes mellitus (n = 5,757)</cell><cell>2,619 (46)</cell></row><row><cell>Asthma/COPD (n = 8,555)</cell><cell>2,975 (35)</cell></row><row><cell>Renal dysfunction (n = 8,555)</cell><cell>483 (6)</cell></row><row><cell>Clinical findings</cell><cell></cell></row><row><cell>Heart rate (n = 8,511), bpm</cell><cell>83.3 ± 14.13</cell></row><row><cell>Number of angina attacks/week (n = 8,207)</cell><cell>2.1 ± 2.79</cell></row><row><cell>Use of short-acting nitrates/week (n = 7,593)</cell><cell>2.8 ± 3.95</cell></row><row><cell>Quality of life a</cell><cell></cell></row><row><cell>EQ-5D index (n = 2,257)</cell><cell>0.66 ± 0.27</cell></row><row><cell>EQ VAS scores (n = 2,170)</cell><cell>57.4 ± 18.30</cell></row><row><cell>CCS classification (n = 8,091)</cell><cell></cell></row><row><cell>Class I</cell><cell>2,163 (27)</cell></row><row><cell>Class II</cell><cell>4,264 (53)</cell></row><row><cell>Class III</cell><cell>1,600 (20)</cell></row><row><cell>Class IV</cell><cell>64 (&lt;1)</cell></row><row><cell>Medication</cell><cell></cell></row><row><cell>Beta-blockers (n = 8,539)</cell><cell>3,413 (40)</cell></row><row><cell>Metoprolol (n = 8,555)</cell><cell>1,376 (16)</cell></row><row><cell>ACE inhibitors (n = 8,555)</cell><cell>4,205 (49)</cell></row><row><cell>Calcium antagonists (n = 8,555)</cell><cell>1,597 (19)</cell></row><row><cell>Long-acting nitrates (n = 8,555)</cell><cell>1,518 (18)</cell></row><row><cell>Molsidomine (n = 8,555)</cell><cell>1,102 (13)</cell></row><row><cell>Aspirin (n = 8,555)</cell><cell>6,569 (77)</cell></row><row><cell>Statins (n = 8,555)</cell><cell>5,473 (64)</cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_2"><head>Table 3 .</head><label>3</label><figDesc><div><p><s>Quality of life after 4 months of treatment with ivabradine in different subpopulations</s></p></div></figDesc><table><row><cell></cell><cell cols="2">EQ-5D index</cell><cell></cell><cell cols="2">EQ VAS score</cell><cell></cell></row><row><cell></cell><cell>n</cell><cell>baseline</cell><cell>change from</cell><cell>n</cell><cell>baseline</cell><cell>change from</cell></row><row><cell></cell><cell></cell><cell></cell><cell>baseline*</cell><cell></cell><cell></cell><cell>baseline*</cell></row><row><cell>Overall</cell><cell>2,171</cell><cell>0.66±0.27</cell><cell>0.17±0.23</cell><cell>2,037</cell><cell cols="2">57.4±18.30 15.4±15.55</cell></row><row><cell cols="3">Demographic characteristics and heart rate</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Women</cell><cell>872</cell><cell>0.62±0.28</cell><cell>0.18±0.24</cell><cell>824</cell><cell cols="2">55.2±18.21 15.9±15.65</cell></row><row><cell>≥75 years</cell><cell>442</cell><cell>0.57±0.28</cell><cell>0.17±0.26</cell><cell>419</cell><cell cols="2">52.8±17.50 14.7±15.24</cell></row><row><cell>≥70 bpm</cell><cell>1,995</cell><cell>0.66±0.26</cell><cell>0.17±0.23</cell><cell>1,870</cell><cell cols="2">57.2±18.23 15.7±15.54</cell></row><row><cell>CCS classification</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Class I</cell><cell>578</cell><cell>0.77±0.22</cell><cell>0.11±0.18</cell><cell>565</cell><cell>65.3±17.37</cell><cell>6.3±9.60</cell></row><row><cell>Class II</cell><cell>989</cell><cell>0.66±0.23</cell><cell>0.17±0.21</cell><cell>972</cell><cell>57.1±16.81</cell><cell>8.6±10.87</cell></row><row><cell>Class III</cell><cell>379</cell><cell>0.49±0.29</cell><cell>0.26±0.28</cell><cell>375</cell><cell cols="2">46.1±15.63 11.5±11.60</cell></row><row><cell>Medical history</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Previous PCI</cell><cell>1,044</cell><cell>0.67±0.26</cell><cell>0.15±0.22</cell><cell>981</cell><cell cols="2">58.7±18.50 14.2±14.97</cell></row><row><cell>Previous MI</cell><cell>1,371</cell><cell>0.67±0.26</cell><cell>0.16±0.22</cell><cell>1,284</cell><cell cols="2">58.5±18.30 15.1±15.54</cell></row><row><cell>Diabetes</cell><cell>726</cell><cell>0.60±0.29</cell><cell>0.19±0.25</cell><cell>687</cell><cell cols="2">54.4±18.12 15.9±16.15</cell></row><row><cell>Asthma/COPD</cell><cell>419</cell><cell>0.58±0.31</cell><cell>0.18±0.27</cell><cell>392</cell><cell cols="2">53.6±18.07 15.8±16.15</cell></row><row><cell>Renal dysfunction</cell><cell>162</cell><cell>0.51±0.31</cell><cell>0.21±0.30</cell><cell>150</cell><cell cols="2">48.4±16.93 16.2±16.94</cell></row><row><cell>Medication</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Any beta-blockers</cell><cell>2,145</cell><cell>0.66±0.27</cell><cell>0.17±0.23</cell><cell>2,012</cell><cell cols="2">57.4±18.27 15.3±15.55</cell></row><row><cell>Metoprolol</cell><cell>905</cell><cell>0.67±0.27</cell><cell>0.16±0.23</cell><cell>859</cell><cell cols="2">57.7±18.25 14.7±15.49</cell></row><row><cell>Metoprolol and ≥70 bpm</cell><cell>828</cell><cell>0.68±0.26</cell><cell>0.16±0.22</cell><cell>784</cell><cell cols="2">57.5±18.24 15.2±15.43</cell></row><row><cell cols="4">Values are means ± SD. * p &lt; 0.0001 for all changes from baseline.</cell><cell></cell><cell></cell><cell></cell></row></table></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">Cardiology 2016;135:141-150 DOI: 10.1159/000447443</note>
		</body>
		<back>

			<div type="acknowledgement">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Acknowledgments</head><p><s>The authors would like to thank all participating investigators for their contributions to the studies analyzed in this publication.</s><s>We thank Julie Salzmann, PhD, who provided medical writing assistance on behalf of Servier, France.</s></p></div>
			</div>

			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Conflict of Interest</head><p><s>K. Werdan has been engaged in ivabradine clinical trials fully or partly supported by Servier, has received honoraria for lectures from Servier, was a member of the German ivabradine advisory board of Servier, and received research grants for experimental and clinical ivabradine research from Servier.</s><s>T. Meinertz was a member of the German ivabradine advisory board of Servier.</s><s>S. Perings, R. Köster, M. Kelm, and U. Müller-Werdan report no conflicts of interest.</s><s>G. Stöckl is an employee of Servier (Medical Affairs).</s><s>This pooled analysis was funded by Servier.</s></p></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">Role of increases in heart rate in determining the occurrence and frequency of myocardial ischemia during daily life in patients with stable coronary artery disease</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Panza</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">G</forename><surname>Diodati</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">S</forename><surname>Callahan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">E</forename><surname>Epstein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">A</forename><surname>Quyyumi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Am Coll Cardiol</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="page" from="1092" to="1098" />
			<date type="published" when="1992">1992</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">Subsets of ambulatory myocardial ischemia based on heart rate activity. Circadian distribution and response to anti-ischemic medication. The Angina and Silent Ischemia Study Group (ASIS)</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">C</forename><surname>Andrews</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Fenton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Toyosaki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">P</forename><surname>Glasser</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">M</forename><surname>Young</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Maccallum</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">S</forename><surname>Gibson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">L</forename><surname>Shook</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">H</forename><surname>Stone</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Circulation</title>
		<imprint>
			<biblScope unit="volume">88</biblScope>
			<biblScope unit="page" from="92" to="100" />
			<date type="published" when="1993">1993</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Ivabradine: the hope for a good treatment of ischemic heart disease</title>
		<author>
			<persName><forename type="first">G</forename><surname>Riccioni</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Curr Med Chem</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="page" from="1817" to="1823" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology</title>
		<author>
			<persName><forename type="first">G</forename><surname>Montalescot</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Sechtem</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Achenbach</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Andreotti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Arden</forename><forename type="middle">C</forename><surname>Budaj</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur Heart J</title>
		<imprint>
			<biblScope unit="volume">34</biblScope>
			<biblScope unit="page" from="2949" to="3003" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">I f inhibition in cardiovascular diseases</title>
		<author>
			<persName><forename type="first">C</forename><surname>Thollon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Vilaine</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Adv Pharmacol</title>
		<imprint>
			<biblScope unit="volume">59</biblScope>
			<biblScope unit="page" from="53" to="92" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">Impact of ivabradine on central aortic blood pressure and myocardial perfusion in patients with stable coronary artery disease</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">G</forename><surname>Dillinger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Maher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Vitale</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Henry</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Logeart</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">S</forename><surname>Manzo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Allee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">I</forename><surname>Levy</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Hypertension</title>
		<imprint>
			<biblScope unit="volume">66</biblScope>
			<biblScope unit="page" from="1138" to="1144" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Ivabradine and bisoprolol on Doppler-derived coronary flow velocity reserve in patients with stable coronary artery disease: beyond the heart rate</title>
		<author>
			<persName><forename type="first">E</forename><surname>Tagliamonte</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Cirillo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Rigo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Astarita</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Coppola</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Romano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Capuano</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Adv Ther</title>
		<imprint>
			<biblScope unit="volume">32</biblScope>
			<biblScope unit="page" from="757" to="767" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">P6291: heart rate reduction by ivabradine for improvement of endothelial function in patients with coronary artery disease: the randomized open-label RIVENDEL study</title>
		<author>
			<persName><forename type="first">F</forename><surname>Mangiacapra</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Colaiori</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Ricottini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Balducci</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Creta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Demartini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Di</forename><surname>Sciascio</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur Heart J</title>
		<imprint>
			<biblScope unit="volume">36</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page">1105</biblScope>
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note>suppl</note>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">The effect of heart rate reduction by ivabradine on collateral function in patients with chronic stable coronary artery disease</title>
		<author>
			<persName><forename type="first">S</forename><surname>Gloekler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Traupe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Stoller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Schild</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Steck</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Khattab</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Vogel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Seiler</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Heart</title>
		<imprint>
			<biblScope unit="volume">100</biblScope>
			<biblScope unit="page" from="160" to="166" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Antianginal and antiischemic effects of ivabradine, an I f inhibitor, in stable angina: a randomized, double-blind, multicentered, placebo-controlled trial</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">S</forename><surname>Borer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Fox</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Jaillon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Lerebours</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Circulation</title>
		<imprint>
			<biblScope unit="volume">107</biblScope>
			<biblScope unit="page" from="817" to="823" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Longterm safety and efficacy of ivabradine in patients with chronic stable angina</title>
		<author>
			<persName><forename type="first">L</forename><surname>Lopez-Bescos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Filipova</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Martos</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cardiology</title>
		<imprint>
			<biblScope unit="volume">108</biblScope>
			<biblScope unit="page" from="387" to="396" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Antianginal efficacy and safety of ivabradine compared with amlodipine in patients with stable effort angina pectoris: a 3-month randomised, double-blind, multicentre, noninferiority trial</title>
		<author>
			<persName><forename type="first">W</forename><surname>Ruzyllo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Tendera</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Ford</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">M</forename><surname>Fox</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Drugs</title>
		<imprint>
			<biblScope unit="volume">67</biblScope>
			<biblScope unit="page" from="393" to="405" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">Efficacy of ivabradine, a new selective I f inhibitor, compared with atenolol in patients with chronic stable angina</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Tardif</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Ford</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Tendera</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">G</forename><surname>Bourassa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Fox</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur Heart J</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="page" from="2529" to="2536" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Efficacy of the I f current inhibitor ivabradine in patients with chronic stable angina receiving betablocker therapy: a 4 month, randomized, placebo-controlled trial</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Tardif</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Ponikowski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Kahan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur Heart J</title>
		<imprint>
			<biblScope unit="volume">30</biblScope>
			<biblScope unit="page" from="540" to="548" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title/>
		<author>
			<persName><surname>Werdan</surname></persName>
		</author>
		<idno type="DOI">10.1159/000447443</idno>
	</analytic>
	<monogr>
		<title level="j">Cardiology</title>
		<imprint>
			<biblScope unit="volume">135</biblScope>
			<biblScope unit="page" from="141" to="150" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<monogr>
		<ptr target="http://www.ema.europa.eu/ema/(accessedNovember17" />
		<title level="m">European Medicines Agency: Procoralan: EPAR -Product Information</title>
				<imprint>
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Efficacy of I f inhibition with ivabradine in different subpopulations with stable angina pectoris</title>
		<author>
			<persName><forename type="first">M</forename><surname>Tendera</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Borer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Tardif</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cardiology</title>
		<imprint>
			<biblScope unit="volume">114</biblScope>
			<biblScope unit="page" from="116" to="125" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">A literature review on the representativeness of randomized controlled trial samples and implications for the external validity of trial results</title>
		<author>
			<persName><forename type="first">T</forename><surname>Kennedy-Martin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Curtis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Faries</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Robinson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Johnston</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Trials</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="page">495</biblScope>
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Ivabradine in combination with beta-blocker improves symptoms and quality of life in patients with stable angina pectoris: results from the AD-DITIONS study</title>
		<author>
			<persName><forename type="first">K</forename><surname>Werdan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Ebelt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Nuding</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Höpfner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Hack</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Müller-Werdan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Res Cardiol</title>
		<imprint>
			<biblScope unit="volume">101</biblScope>
			<biblScope unit="page" from="365" to="373" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Treatment of stable angina pectoris by ivabradine in every day practice: the REDUCTION study</title>
		<author>
			<persName><forename type="first">R</forename><surname>Köster</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Kaehler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Meinertz</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am Heart J</title>
		<imprint>
			<biblScope unit="volume">158</biblScope>
			<biblScope unit="page" from="e51" to="e57" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">Ivabradine treatment in chronic stable angina patients with or without concomitant beta-blocker therapy: effectiveness, treatment response and tolerability in clinical practice</title>
		<author>
			<persName><forename type="first">S</forename><surname>Perings</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Stöckl</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Res Cardiol</title>
		<imprint>
			<biblScope unit="volume">103</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page">102</biblScope>
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">Ivabradine in combination with beta-blockers in patients with chronic stable angina after percutaneous coronary intervention</title>
		<author>
			<persName><forename type="first">K</forename><surname>Werdan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Ebelt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Nuding</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Höpfner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Stöckl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Müller-Werdan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Adv Ther</title>
		<imprint>
			<biblScope unit="volume">32</biblScope>
			<biblScope unit="page" from="120" to="137" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">Ivabradine in combination with metoprolol improves symptoms and quality of life in patients with stable angina pectoris: a post hoc analysis from the ADDITIONS trial</title>
		<author>
			<persName><forename type="first">K</forename><surname>Werdan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Ebelt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Nuding</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Höpfner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Stöckl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Müller-Werdan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cardiology</title>
		<imprint>
			<biblScope unit="volume">133</biblScope>
			<biblScope unit="page" from="83" to="90" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">Eligibility criteria of randomized controlled trials published in high-impact general medical journals: a systematic sampling review</title>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">G</forename><surname>Van Spall</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Toren</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Kiss</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Fowler</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">JAMA</title>
		<imprint>
			<biblScope unit="volume">297</biblScope>
			<biblScope unit="page" from="1233" to="1240" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">Management of drug therapy in the elderly</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">C</forename><surname>Montamat</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">J</forename><surname>Cusack</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">E</forename><surname>Vestal</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">321</biblScope>
			<biblScope unit="page" from="303" to="309" />
			<date type="published" when="1989">1989</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">Management of patients with stable angina and type 2 diabetes</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">C</forename><surname>Deedwania</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Rev Cardiovasc Med</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="page" from="105" to="113" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">Prognostic impact of the presence and absence of angina on mortality and cardiovascular outcomes in patients with type 2 diabetes and stable coronary artery disease: results from the BARI 2D (Bypass Angioplasty Revascularization Investigation 2 Diabetes) trial</title>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">R</forename><surname>Dagenais</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Lu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">P</forename><surname>Faxon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Bogaty</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Adler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Fuentes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Escobedo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Krishnaswami</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Slater</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">L</forename><surname>Frye</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Am Coll Cardiol</title>
		<imprint>
			<biblScope unit="volume">61</biblScope>
			<biblScope unit="page" from="702" to="711" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">Efficacy of ivabradine, a selective I f inhibitor, in patients with chronic stable angina pectoris and diabetes mellitus</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">S</forename><surname>Borer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Tardif</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Cardiol</title>
		<imprint>
			<biblScope unit="volume">105</biblScope>
			<biblScope unit="page" from="29" to="35" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">R: Cardiac autonomic neuropathy in diabetes: a clinical perspective</title>
		<author>
			<persName><surname>Pop-Busui</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Diabetes Care</title>
		<imprint>
			<biblScope unit="volume">33</biblScope>
			<biblScope unit="page" from="434" to="441" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">Resting heart rate in patients with stable coronary artery disease and diabetes: a report from the Euro Heart Survey on Diabetes and the Heart</title>
		<author>
			<persName><forename type="first">M</forename><surname>Anselmino</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Ohrvik</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Rydén</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur Heart J</title>
		<imprint>
			<biblScope unit="volume">31</biblScope>
			<biblScope unit="page" from="3040" to="3045" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">Rumsfeld JS: Angina at 1 year after myocardial infarction: prevalence and associated findings</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">M</forename><surname>Maddox</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">J</forename><surname>Reid</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Spertus</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Mittleman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">M</forename><surname>Krumholz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Parashar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">M</forename><surname>Ho</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arch Intern Med</title>
		<imprint>
			<biblScope unit="volume">168</biblScope>
			<biblScope unit="page" from="1310" to="1316" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">Quality of life of patients with chronic stable angina before and four years after coronary revascularisation compared with a normal population</title>
		<author>
			<persName><forename type="first">B</forename><surname>Brorsson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Bernstein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">H</forename><surname>Brook</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Werkö</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Heart</title>
		<imprint>
			<biblScope unit="volume">87</biblScope>
			<biblScope unit="page" from="140" to="145" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main">Ivabradine reduces myocardial stunning in patients with exercise-inducible ischaemia</title>
		<author>
			<persName><forename type="first">F</forename><surname>Maranta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Tondi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Agricola</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Margonato</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Rimoldi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">G</forename><surname>Camici</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Basic Res Cardiol</title>
		<imprint>
			<biblScope unit="volume">110</biblScope>
			<biblScope unit="page">55</biblScope>
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main">Effect of ivabradine on left ventricular remodelling after reperfused myocardial infarction: a pilot study</title>
		<author>
			<persName><forename type="first">E</forename><surname>Gerbaud</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Montaudon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Chasseriaud</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Gilbert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Cochet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Pucheu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Horovitz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Bonnet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Douard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Coste</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arch Cardiovasc Dis</title>
		<imprint>
			<biblScope unit="volume">107</biblScope>
			<biblScope unit="page" from="33" to="41" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title level="a" type="main">Prevalence of obstructive coronary artery disease in ambulatory patients with stable angina pectoris</title>
		<author>
			<persName><forename type="first">D</forename><surname>Westermann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Savvatis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Wollenberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Limberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">S</forename><surname>Maier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Bauersachs</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Exp Cardiol</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="page">387</biblScope>
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main">Recurrent angina after coronary angioplasty: mechanisms, diagnostic and therapeutic options</title>
		<author>
			<persName><forename type="first">P</forename><surname>Izzo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Macchi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>De Gennaro</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Gaglione</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Di</forename><surname>Biase</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Brunetti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">D</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur Heart J Acute Cardiovasc Care</title>
		<imprint>
			<biblScope unit="volume">1</biblScope>
			<biblScope unit="page" from="158" to="169" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title level="a" type="main">Ivabradine in stable coronary artery disease without clinical heart failure</title>
		<author>
			<persName><forename type="first">K</forename><surname>Fox</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Ford</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">G</forename><surname>Steg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Tardif</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Tendera</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Ferrari</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">371</biblScope>
			<biblScope unit="page" from="1091" to="1099" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b37">
	<analytic>
		<title level="a" type="main">Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial</title>
		<author>
			<persName><forename type="first">K</forename><surname>Fox</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Ford</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">G</forename><surname>Steg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Tendera</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Ferrari</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet</title>
		<imprint>
			<biblScope unit="volume">372</biblScope>
			<biblScope unit="page" from="807" to="816" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b38">
	<analytic>
		<title level="a" type="main">Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study</title>
		<author>
			<persName><forename type="first">K</forename><surname>Swedberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Komajda</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Böhm</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">S</forename><surname>Borer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Ford</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Dubost-Brama</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Lerebours</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Tavazzi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet</title>
		<imprint>
			<biblScope unit="volume">376</biblScope>
			<biblScope unit="page" from="875" to="885" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b39">
	<analytic>
		<title level="a" type="main">Heart rate and use of beta-blockers in stable outpatients with coronary artery disease</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">G</forename><surname>Steg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Ferrari</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Ford</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Greenlaw</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Tardif</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Tendera</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Abergel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">M</forename><surname>Fox</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">PLoS One</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="page">e36284</biblScope>
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
